What stands out
- Compounded semaglutide and tirzepatide pages
- Video consultation described
What to weigh
- The lowest medication quote is not a complete monthly total.
- Provider performance is not established by branded-drug trial results.
The menu spans several product categories
Mochi’s current site lists compounded preparations alongside branded medications and other care categories. This review focuses on its compounded injectable semaglutide and tirzepatide options, which have dedicated product pages.[source]
A broad menu should not blur the distinction between a branded approved medicine and a compounded preparation. The exact prescription and formulation need to be identified before discussing evidence or cost.
Starting medication prices are dose-dependent
The reviewed pages advertise compounded semaglutide as low as $60 and compounded tirzepatide as low as $90, plus membership. Both explicitly say the medication price varies with the prescribed dose.[source][source]
The current homepage also promotes an initial annual membership offer of $199 due upfront. Confirm eligibility, renewal and the applicable membership plan rather than treating the displayed monthly equivalent as a monthly charge.[source]
Compounded products need their own evidence boundary
FDA states that compounded GLP-1 medicines are not approved finished products and identifies concerns with unapproved versions, including dosing errors and salt forms. Ask the clinician and pharmacy to explain the proposed preparation.[source]
The SURMOUNT-5 outcome cannot be applied to Mochi’s compounded injections or used as a platform success rate. Ingredient overlap does not establish that a different finished preparation has the same clinical evidence.[source]
Ask how medication and membership fit together
Clarify which visits are included, which services are additional, the dispensing pharmacy and the route for urgent medication questions. We have not independently measured appointment availability or support response times.
Also ask how the bill changes after a clinical adjustment. A dose-dependent offer makes the ongoing budget a different question from the initial starting price.
Compare a written selected-plan quote
Mochi is a useful comparison for readers evaluating a membership-based service with a wide medication menu. The low starting medication figures are incomplete until dose and membership are included.
The semaglutide and tirzepatide reviews preserve those distinctions. No provider is assigned a clinical rank from a medication trial it did not conduct.
Sources & further reading
Provider pages establish what a brand markets. Clinical and regulatory sources establish the limits of the evidence. Each source has its own last-checked date below.
- Mochi Health: current care modelProvider membership and care overview · Checked October 8, 2026
- Mochi: compounded semaglutideStarting medication quote; dose-dependent; membership extra · Checked October 8, 2026
- Mochi: compounded tirzepatideStarting medication quote; dose-dependent; membership extra · Checked October 8, 2026
- FDA: concerns with unapproved GLP-1 drugsCompounded-product risks, salt forms, dosing errors and online red flags · Checked October 10, 2026
- Aronne et al., NEJM 2025: tirzepatide compared with semaglutide for obesityPrimary randomized trial abstract; SURMOUNT-5, 751 adults without diabetes, 72 weeks; funded by Eli Lilly · Checked October 8, 2026